Wet age-related macular degeneration (wet AMD) is a leading cause of vision loss in older adults, responsible for around 90% of AMD-related blindness. Though it only makes up about 10% of AMD cases, it can cause rapid, severe vision loss, affecting an estimated 1.49 million people in the United States alone. As the population ages, these numbers are expected to rise, making wet AMD a growing concern.
Fortunately, anti-VEGF injections like Eylea (aflibercept) and Avastin (bevacizumab) have revolutionized wet AMD treatment. Eylea, FDA-approved, blocks VEGF to prevent abnormal blood vessel growth and is given every 8 weeks after an initial loading phase. Avastin, originally for cancer, is used off-label in ophthalmology, offering similar results at a lower cost but requiring monthly injections.
In this article, we’ll compare Eylea and Avastin, diving into their pharmacology, dosing schedules, clinical effectiveness, safety profiles, and real-world considerations. By understanding the differences between these two treatments, healthcare providers can make better-informed, personalized treatment decisions for managing wet AMD.
Key Takeaways
- Eylea (aflibercept) is FDA-approved for treating several retinal conditions, including wet AMD, diabetic macular edema (DME), and retinal vein occlusion (RVO). It works by blocking VEGF and using a decoy receptor mechanism.
- Avastin (bevacizumab) is FDA-approved for cancer but is commonly used off-label for wet AMD and other retinal conditions. It also blocks VEGF-A but requires compounding for ophthalmic use.
- Eylea typically has a dosing schedule of 2 mg every 8 weeks after an initial loading phase, while Avastin is given every 4 to 6 weeks.
- Eylea is more expensive due to its FDA-approved labeling and structured dosing regimen, whereas Avastin is more affordable but requires off-label use and compounding.
- Both treatments have similar side effects, including eye pain, eye irritation, and blurred vision. Rare but serious adverse events include endophthalmitis and increased intraocular pressure.
About: Medica Depot is your trusted all-in-one supplier, offering a range of high-quality medical injectables and supplies. If you’re looking to buy Eylea, contact Medica Depot’s sales representatives and they will guide you on how to do so. Whether for health professionals, plastic surgeons, dermatologists, licensed estheticians, or other specialists, we can offer genuine, brand-name products you may need. With Medica Depot, we prioritize serving you better to improve the patient’s quality of life.
Eylea and Avastin: Regulatory Status and Indication Differences
When comparing aflibercept vs bevacizumab, healthcare professionals must carefully review their regulatory approvals to ensure they are using these medications within their approved indications. This is essential to minimize potential risks and complications while optimizing patient care. By understanding the Eylea prescribing information and Avastin’s off-label use, clinicians can guide their treatment decisions confidently, ensuring safe and effective outcomes.
FDA Approval and Indications
Both Eylea and Avastin have FDA approval, but for different indications:
Eylea Approved Uses
- Neovascular (wet) age-related macular degeneration (AMD)
- Macular edema following retinal vein occlusion (RVO)
- Diabetic macular edema (DME)
- Diabetic retinopathy (DR)
- Retinopathy of prematurity (ROP)
Avastin Approved Indications
- Metastatic colorectal carcinoma
- Non-small cell lung cancer
- Glioblastoma multiforme
- Renal cell carcinoma
- Cervical and ovarian cancers
While Avastin was initially approved for oncology uses, it is frequently used off-label for ophthalmic conditions such as wet AMD, DME, and RVO. By comparing Eylea vs Avastin, clinicians can select the most appropriate anti-VEGF agent based on efficacy, cost, and patient-specific factors.
Mechanism of Action and Binding Profiles of These Eye Medications
Both Eylea and Avastin work by blocking VEGF-driven angiogenesis, but they have distinct molecular designs and binding profiles, which influence their efficacy and duration of action.
Eylea Injections: Decoy Receptor Binding Profile
Eylea is a recombinant fusion protein that combines the VEGF-binding domains of VEGFR-1 and VEGFR-2. It has picomolar affinity for VEGF-A, VEGF-B, and placental growth factor (PIGF), preventing these ligands from binding to endothelial VEGF receptors, thereby halting abnormal blood vessel growth and vascular leakage.
Avastin: Monoclonal Antibody Binding Profile
Avastin, a humanized IgG1 monoclonal antibody, targets only VEGF-A. It binds to all biologically active VEGF-A isoforms with nanomolar affinity, inhibiting its action on endothelial cells and reducing neovascularization and edema.
Both drugs block VEGF, but Eylea’s broader binding profile and longer-lasting effects provide advantages in terms of treatment flexibility and dosing intervals.
Cost, Dosing Schedules, and Accessibility Factors
Clinicians must carefully balance drug acquisition costs, insurance coverage, and dosing schedules when choosing between Eylea and Avastin. The cost considerations for each therapy differ significantly, and Eylea is typically more expensive due to its FDA-approved ophthalmic labeling, while Avastin offers a more affordable off-label alternative.
- Eylea Dosing Schedule: For conditions like wet AMD and DME, Eylea is typically dosed as 2 mg (0.05 mL) for the first three monthly injections, followed by maintenance doses every 8 weeks. This structured regimen allows Eylea to maintain consistent drug levels over time, providing predictable outcomes.
- Avastin Dosing Schedule: Administered as 1.25 mg every 4 to 6 weeks. While it is similar to Eylea in mechanism of action, its dosing frequency can be a downside for some patients who prefer longer intervals between injections.
The cost difference is notable: Avastin is more affordable, but Eylea‘s FDA-approved labeling simplifies stocking, billing, and coding, offering clear advantages in clinic management. Clinicians must consider regional variations in drug pricing, insurance plans, and patient needs when making their decisions.
Safety, Compounding, and Real-World Considerations of Eylea and Avastin
Anti-VEGF drugs such as Eylea (aflibercept) and Avastin (bevacizumab) have transformed how ophthalmologists manage retinal diseases like wet AMD, diabetic macular edema, and retinal vein occlusion.
While both belong to the same class of anti-VEGF treatments, their safety profiles, handling protocols, and real-world access differ in important ways. For patients, understanding these distinctions is critical to making informed choices about their eye treatment options.
Common Eylea Side Effects
Supported by strong clinical data on its effectiveness, Eylea injections have led to widespread use in clinical practice. Most patients tolerate the therapy well, but side effects may occur.
Common ocular side effects of Eylea include:
- Eye pain
- Eye irritation
- Blurred vision
More serious but rare side effects include:
- Increased intraocular pressure (IOP)
- Endophthalmitis (eye infection)
- Conjunctival hemorrhage (eye redness)
Ophthalmologists routinely monitor for these complications during follow-up visits, ensuring that Eylea treatments remain both safe and effective. The single-use vial design also minimizes risks linked to contamination, making Eylea a straightforward choice for consistent outcomes.
Common Avastin Side Effects
Although the manufacturer originally developed Avastin as an oncology drug, practitioners widely use it off-label as an anti-VEGF treatment in ophthalmology. Like Eylea, it works by blocking VEGF to prevent abnormal vessel growth in the eye.
For Avastin, side effects are similar, with common ocular issues including:
- Eye irritation
- Conjunctival hemorrhage
- Eye discomfort
Serious side effects like endophthalmitis and increased IOP can also occur, but are less frequent than with Eylea.
Compounding and Handling Protocols
One of the clearest differences between Eylea and Avastin lies in how they are prepared for use.
- Eylea injections: Supplied in preservative-free, single-use vials or prefilled syringes. This reduces the risk of compounding errors, contamination, and dosing inconsistencies. Ophthalmologists can administer the drug directly, streamlining inventory and treatment delivery.
- Avastin treatments: Require compounding into smaller doses suitable for intravitreal injection. This must be done in ISO-classified cleanrooms under strict aseptic protocols. Any deviation raises the risk of microbial contamination or dosing variability, which can impact both safety and effectiveness.
For these reasons, Eylea treatment is often preferred when consistency and regulatory oversight are priorities, while Avastin remains an option when cost pressures drive decision-making.
Real-World Access and Reimbursement
The cost and accessibility of Eylea and Avastin also depend on insurance coverage and reimbursement policies. Eylea, being FDA-approved for ophthalmic use, qualifies for medical reimbursement and is supported by Regeneron’s copay assistance programs, making it easier for patients to access treatment.
Cost and access remain major factors in choosing between anti-VEGF drugs.
- Eylea treatment: FDA-approved for multiple retinal conditions, supported by well-established clinical trial data, and eligible for medical reimbursement. Regeneron also provides copay assistance programs, making it easier for patients to access care.
- Avastin treatment: Less expensive per injection, but used off-label. It requires informed consent and prior authorization. Compounding demands can also lead to supply inconsistencies, potentially delaying treatment for some patients.
In real-world practice, ophthalmologists weigh these trade-offs—balancing safety, regulatory approval, and affordability—when recommending the right option for each individual.
Conclusion
Both Eylea and Avastin are effective options for treating wet AMD and other retinal conditions. Eylea has FDA approval for multiple ophthalmic conditions and offers a decoy receptor mechanism to inhibit VEGF activity. Avastin, while approved for cancer treatments, is used off-label in ophthalmology with similar efficacy at a lower cost.
The choice between Eylea and Avastin depends on factors like cost, dosing frequency, patient preferences, and clinical needs. By understanding each drug’s efficacy, safety profile, and dosing protocols, clinicians can select the most appropriate treatment to optimize patient outcomes and manage wet AMD effectively.
FAQs
1. What conditions do Eylea and Avastin treat?
Eylea is FDA-approved for wet Age-Related Macular Degeneration, diabetic macular edema, and other eye conditions. The FDA primarily approved Avastin for cancer, but often used off-label for eye diseases like wet AMD.
2. How do Eylea and Avastin differ in their mechanisms of action?
Eylea acts as a decoy receptor, blocking multiple VEGF isoforms to prevent abnormal blood vessel growth. Avastin is a monoclonal antibody that specifically targets and inhibits VEGF-A.
3. What are the dosing schedules for Eylea and Avastin?
Clinicians typically administer Eylea as 2 mg injections every four weeks, which may change to every eight weeks. On the other hand, they give Avastin as 1.25 mg injections every four to six weeks, adapting to patient needs.
References
Rein DB, Wittenborn JS, Burke-Conte Z, et al. Prevalence of Age-Related Macular Degeneration in the US in 2019. JAMA Ophthalmology. 2022;140(12):1202. doi:10.1001/jamaophthalmol.2022.4401
Rein DB, Wittenborn JS, Burke-Conte Z, et al. Prevalence of Age-Related Macular Degeneration in the United States in 2019. Vision and Eye Health Surveillance System. Centers for Disease Control and Prevention. Published 2022. https://www.cdc.gov/vision-health-data/prevalence-estimates/amd-prevalence.html
Grisanti S, Ziemssen F. Bevacizumab: off-label use in ophthalmology. Indian J Ophthalmol. 2007;55(6):417-420. doi:10.4103/0301-4738.36474
Genentech, Inc. HIGHLIGHTS of PRESCRIBING INFORMATION | AVASTIN (Bevacizumab).; 2004. Accessed August 5, 2025. https://www.gene.com/download/pdf/avastin_prescribing.pdf
